MedTrace Logo

Two Schemes Response in Multiple Myeloma

NCT06284395 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 83

Last updated 2024-10-02

No results posted yet for this study

Summary

Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.

Conditions

  • Response, Acute Phase
  • Survivorship

Interventions

DRUG

Bortezomib

Bortezomib 1.3mg/m2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (14,15) (VTD)

Sponsors & Collaborators

  • Hospital General de Mexico

    lead OTHER_GOV

Principal Investigators

  • Adolfo O Martinez Tovar, PhD · Hospital General de México Dr. Eduardo Liceaga

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-20
Primary Completion
2024-03-20
Completion
2024-10-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06284395 on ClinicalTrials.gov